RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Robert Holt to Cancer Vaccines

This is a "connection" page, showing publications Robert Holt has written about Cancer Vaccines.
Connection Strength

0.669
  1. Warren RL, Holt RA. A census of predicted mutational epitopes suitable for immunologic cancer control. Hum Immunol. 2010 Mar; 71(3):245-54.
    View in: PubMed
    Score: 0.354
  2. Fisher SA, Aston WJ, Chee J, Khong A, Cleaver AL, Solin JN, Ma S, Lesterhuis WJ, Dick I, Holt RA, Creaney J, Boon L, Robinson B, Lake RA. Transient Treg depletion enhances therapeutic anti-cancer vaccination. Immun Inflamm Dis. 2017 03; 5(1):16-28.
    View in: PubMed
    Score: 0.142
  3. Martin SD, Brown SD, Wick DA, Nielsen JS, Kroeger DR, Twumasi-Boateng K, Holt RA, Nelson BH. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. PLoS One. 2016; 11(5):e0155189.
    View in: PubMed
    Score: 0.137
  4. Chee J, Robinson BW, Holt RA, Creaney J. Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies. Chest. 2017 Apr; 151(4):891-897.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support